Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Pharmacokinetic Models: Overview

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of cash and near-cash social policies on substance use outcomes: a scoping review.

Health affairs scholar·2026

Same author

Association of Continuous Medicaid Eligibility With Postpartum Coverage and Opioid Use Disorder Treatment.

American journal of preventive medicine·2026

Same author

Recovery of Pregnancy-Related Death Ratios After the Coronavirus Disease 2019 (COVID-19) Pandemic: Disparities by Age, Race and Ethnicity, and Geography.

Obstetrics and gynecology·2026

Same author

Maternal postpartum mood and anxiety disorder symptoms and parent-reported infant health-related quality of life at 1 year: a cohort study.

Archives of disease in childhood·2025

Same author

Continuous Medicaid Eligibility, Child Insurance, and Health Care Use.

Pediatrics·2025

Same author

New York's Basic Health Program Increased Subsidized Insurance Coverage From Preconception To The Postpartum Period.

Health affairs (Project Hope)·2025

Same journal

Use of Publicly Reported Surgical Wait Time Information by Community Family Physicians in Toronto, Canada.

Healthcare policy = Politiques de sante·2026

Same journal

A Population-Based Comparison of Wait Times for Common Elective General Surgery Procedures Between Immigrants and Non-Immigrants in British Columbia.

Healthcare policy = Politiques de sante·2026

Same journal

Expanding Surgical Access in Canada Through Self-Governing First Nations.

Healthcare policy = Politiques de sante·2026

Same journal

Commentary: Gender Equity Is Essential for Optimal Surgical Prioritization: A Response to Quinn and Brennand.

Healthcare policy = Politiques de sante·2026

Same journal

Efficiency Through Equity: Prioritizing Gynecologic Surgery to Improve Health System Performance.

Healthcare policy = Politiques de sante·2026

Same journal

Commentary: Simple Policy, Entrenched System: Lessons From Post-Sedation Accompaniment.

Healthcare policy = Politiques de sante·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Canadian pharmacare: looking back, looking forward.

Steven G Morgan¹, Jamie R Daw

¹Associate Professor and Associate Director, Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, BC.

Healthcare Policy = Politiques De Sante

|August 24, 2013

Summary

This summary is machine-generated.

Canadian pharmacare is incomplete, leaving prescription drug costs uncovered by universal health insurance. Public engagement is crucial for future pharmacare reform to address system gaps.

More Related Videos

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Related Experiment Videos

Last Updated: May 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Area of Science:

Health Policy
Public Health
Healthcare Systems

Background:

Canadian medicare, while valued, has significant gaps in coverage.
Prescription drugs represent a major component of healthcare expenditures.
The existing system lacks comprehensive national pharmacare.

Observation:

Universal health insurance in Canada typically excludes prescription medications.
Historical factors have shaped the current fragmented pharmacare landscape.
Demographic shifts and technological advancements are increasing demand for drug coverage.

Findings:

The Canadian healthcare system's pharmacare component is notably deficient.
Past policy decisions have led to the current lack of universal drug coverage.
Future healthcare needs necessitate pharmacare reform.

Implications:

Meaningful public engagement can foster consensus on pharmacare goals.
Increased political support is essential for implementing policy changes.
Addressing pharmacare gaps is vital for equitable and sustainable healthcare in Canada.